References
- Nadar S., Lip G. Y., Beevers D. G. Primary hyperaldosteronism. Ann Clin Biochem 2003; 40: 439–52
- Stowasser M., Gordon R. D. Primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2003; 17: 591–605
- Stowasser M., Gordon R. D. Primary aldosteronism – careful investigation is essential and rewarding. Mol Cell Endocrinol 2004; 217: 33–9
- Young W. F Jr. Mini review: primary aldosteronism – changing concepts in diagnosis and treatment. Endocrinology 2003; 144: 2208–13
- Perschel F. H., Schemer R., Seiler L., Reincke M., Deinum J., Maser‐Gluth C., et al. Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem 2004; 50: 1650–5
- Westerdahl C., Bergenfelz A., Isaksson A., Wihl A., Nerbrand C., Valdemarsson S. High frequency of primary hyperaldosteronism among hypertensive patients from a primary care area in Sweden. Scand J Prim Health Care 2006; 24: 154–9
- Mantero F., Mattarello M. J., Albiger N. M. Detecting and treating primary aldosteronism: primary aldosteronism. Exp Clin Endocrinol Diabetes 2007; 115: 171–4
- Cartledge S., Lawson N. Aldosterone and renin measurements. Ann Clin Biochem 2000; 37(Pt 3)262–78
- Unger N., Lopez Schmidt I., Pitt C., Walz M. K., Philipp T., Mann K., et al. Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass. Eur J Endocrinol 2004; 150: 517–23
- Montori V. M., Young W. F Jr. Use of plasma aldosterone concentration‐to‐plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am 2002; 31: 619–32, xi
- Giacchetti G., Ronconi V., Lucarelli G., Boscaro M., Mantero F. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 2006; 24: 737–45
- Mattsson C., Young W. F Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2006; 2: 198–208, quiz, 191 p following 230
- Schirpenbach C., Reincke M. Screening for primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2006; 20: 369–84
- Stowasser M., Gordon R. D. Monogenic mineralocorticoid hypertension. Best Pract Res Clin Endocrinol Metab 2006; 20: 401–20
- Padfield P. L., Allison M. E., Brown J. J., Ferriss J. B., Fraser R., Lever A. F., et al. Response of plasma aldosterone to fludrocortisone in primary hyperaldosteronism and other forms of hypertension. Clin Endocrinol (Oxf) 1975; 4: 493–500
- Lund J. O., Nielsen M. D. Fludrocortisone suppression test in normal subjects, in patients with essential hypertension and in patients with various forms of aldosteronism. Acta Endocrinol (Copenh) 1980; 93: 100–7
- Ahokoski O., Virtanen A., Kairisto V., Scheinin H., Huupponen R., Irjala K. Biological day‐to‐day variation and reference change limits of serum cortisol and aldosterone in healthy young men on unrestricted diets. Clin Chem 1999; 45: 1097–9
- Plouin P. F., Jeunemaitre X. Would wider screening for primary aldosteronism give any health benefits?. Eur J Endocrinol 2004; 151: 305–8